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Background: Alterations in the microbiome has been postulated to drive inflammation in 
IBD. In this pilot randomized-controlled trial we evaluated the effectiveness of quadruple 
antibiotic cocktail in addition to intravenous-corticosteroids (IVCS) in acute severe colitis 
(ASC).  
 
Design and procedures: Hospitalized children with ASC (PUCAI ≥65) were randomized 
into two arms: the first received antibiotics in addition to IVCS (amoxicillin, vancomycin, 
metronidazole, doxycycline/ciprofloxacin (IVCS+AB)), while the other received only IVCS 
for 14 days. The primary outcome was day-5 disease activity (PUCAI) score. Microbiome 
was analyzed using 16S rRNA gene and metagenome. 
Results: 28 children were included: 16 in the AB+IVCS and 12 in the IVCS arms (mean age 
13.9±4.1 years and 23 (82%) with extensive colitis). The mean day-5 PUCAI was 25±16.7 vs 
40.4±20.4, respectively (p=0.037). Only 3 and 2 children, respectively, required colectomy 
during one-year follow-up (p=0.89). Microbiome data at time of admission were analyzed for 
25 children of whom 17 (68%) had a predominant bacterial species (>33% abundance); 
response was not associated with the specific species while decreased microbiome diversity at 
admission was associated with day-5 response in the IVCS arm. 
 
Conclusion: Patients with ASC have alterations in the microbiome characterized by loss of 
diversity and presence of predominant bacterial species. Quadruple therapy in addition to 
IVCS improved disease activity on day 5, but larger studies are needed to determine whether 






It is believed that the pathogenesis of inflammatory bowel diseases (IBD) is related to 
disequilibrium between an altered immune response and the enteric microbiome. We have 
previously shown in the prospective Outcome of Steroid therapy in Colitis Individuals (OSCI) 
study that children with acute severe colitis (ASC) responding to intravenous steroids have a 
more diverse microbiome than non-responders (1). The mucosa stands as a barrier between 
the microbiome and the host, and thus the increased permeability of the gut seen in IBD may 
be associated with translocation of micro-organisms, triggering chronic inflammation.  
Antibiotic therapy has long been used in IBD with conflicting and varying results (2). In 
ASC, three clinical trials showed no benefit to intravenous antibiotics including 
metronidazole (3), ciprofloxacin (4), and metronidazole with tobramycin (5), all in 
combination with intravenous steroids. In contrast, three other placebo-controlled trials 
showed a significant benefit to oral poorly absorbed antibiotics in ASC, including oral 
tobramycin (6), oral vancomycin (7) and oral rifaximin (8). The effectiveness of oral 
vancomycin was further demonstrated by us and by others in case series, often when used 
primarily to treat primary sclerosing cholangitis (PSC) (9, 10). 
In a series of studies, a Japanese group provided evidence that an anti- Fusobacterium varium 
oral antibiotic cocktail (14 day triple therapy with amoxicillin, metronidazole, and 
tetracycline) may be effective in ulcerative colitis (UC) (11) (12, 13) (14) (15). The cocktail 
showed encouraging results in two cohorts of adults with steroid-refractory and steroid-
dependent UC (12, 13) and in a small randomized controlled trial (RCT) conducted among 
such patients (14). In another RCT of 210 adults with mild to severe UC, improvement at 3 
months was shown in 45% of those receiving the antibiotic cocktail compared to 23% with 
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placebo; remission was superior in the antibiotics arm only at 1 year (15). Other microbes, 
such as Ruminococcus gnavus (16) and E. coli (17) are enriched in the gut of UC patients. 
Even if Fusobacterium are not the causative organism in UC, it is tempting to speculate that 
at least some episodes of ASC are triggered by a yet-unknown enteric infection, similar to 
Clostridium difficile or cytomegalovirus that have been associated with refractory acute 
exacerbations. Based on that speculation and building on the studies with the Japanese 
cocktail and numerous studies on the effect of oral vancomycin, we trialed a quadruple 
therapy cocktail of oral metronidazole, amoxicillin, vancomycin and doxycycline (or 
ciprofloxacin in younger children; hereafter referred to as the Jerusalem cocktail) in children 
with ASC. We published our experience of the first treated 15 children, of whom almost half 
responded (18). Subsequently, Kordy et al reported 8 children with steroid-resistant or 
dependent-UC treated with the cocktail, of whom 7 (88%) responded and 3 (38%) entered 
remission (19). Further data concerning 63 children from Philadelphia treated with various 
versions of the Jerusalem and Japanese cocktails showed overall 40% remission rate at 3 
weeks; 26 of the cohort were hospitalized with ASC of whom 7 (27%) entered remission at 3 
weeks (20).  
Since there are no controlled studies in children to evaluate the effectiveness of antibiotics in 
ASC, we aimed in this PRASCO trial (Pediatric Randomized trial of Antibiotics in acute 
Severe COlitis) to evaluate the effectiveness of the Jerusalem antibiotic cocktail in pediatric 
ASC in a 1-year open label, investigator-blinded RCT. We also aimed to explore the 






This was an “add-on” open label randomized investigator-blinded multi-center international 
trial in children receiving intravenous steroids for ASC, comparing two arms: the first 
received antibiotics in addition to steroids (“AB+IVCS” group), while the other received only 
intravenous steroids (“IVCS” group) (clinicaltrials.gov NCT02033408). The study was 
approved by the local ethics board at each of the participating sites. 
 
Eligibility criteria 
Children aged 2-18 years with established diagnosis of UC using standard criteria (21, 22), 
were eligible if they had severe disease (i.e. pediatric UC activity index (PUCAI)≥65), 
required admission for IVCS and had negative stool analysis for culture, enteric parasites, 
viruses and C. difficile toxins (23). Although the protocol allowed including children with 
Crohn’s colitis, none were eventually included. The protocol initially mandated failing at least 
1-week of oral prednisone and being anti-TNF naive, but these criteria were later removed to 
facilitate recruitment, on condition that the anti-TNF dose has been stable for at least 8 weeks. 
Exclusion criteria were disease confined to the rectum, use of antibiotics during the last 
month, any proven infection, the presence of fever thought to be unrelated to the 
inflammatory process, and known allergy to at least two antibiotics from the cocktail. The 
necessity for initiating immediate treatment in the setup of ASC did not allow for a screening 
period and thus all eligible children were randomized while awaiting stool infectious 
screening; positive results led to immediate exclusion from the trial and the antibiotic 
treatment was discontinued.  
  
Interventions (Table 1, Figure 1 and 2) 
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Patients were randomized into two groups:  
1. The "IVCS" group received standard therapy with methylprednisolone only (1.5mg/kg 
up to 60mg daily in two divided doses) 
2. The “AB+IVCS” group received the steroids as well as oral antibiotics for 3 weeks:  
a. Vancomycin 250mgX4/day (children <8 years of age- 125mgX4/day) 
b. Amoxicillin 50mg/kg/day divided into 3 doses (up to 500mgX3/day) 
c. Metronidazole 5mg/KgX3/day (up to 250mgX3/day) 
d. Doxycycline 2mg/kgX2/day (up to 100mgX2/day) (children <7 years of age 
ciprofloxacin 10mg/KgX2/day (up to 250mgX2/day) 
 
Known allergy to one of the drugs led to substitution with oral gentamicin (2.5mg/KgX3/d). 
Dose was rounded to the closest possible whole pill dose. As recommended in ASC, 5-ASA 
was discontinued upon admission and food continued liberally as tolerated; total parenteral 
nutrition (TPN) was allowed as needed (23). Topical rectal treatment was allowed if 
administered without dose change in the week preceding admission.  
 
Outcomes 
The primary outcome was day-5 PUCAI score, which is used to decide upon second line 
therapy in pediatric ASC (23) and is highly correlated with endoscopic appearance of the 
colonic mucosa with a concordance of >80% (24-27). The European Medicines Agency 
(EMA) recommends using the PUCAI as the primary endpoint when endoscopic assessment 
is not available as in pediatric ASC where sigmoidoscopy is recommended only in non-
responders (23). We supplemented the analysis by serial fecal calprotectin measures as a 
secondary outcome. Other secondary outcomes included remission rates (i.e. PUCAI<10), 
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need for second line therapy (anti TNF, cyclosporine, tacrolimus or colectomy), and rate of C. 
difficile infections after treatment. 
 
Procedures 
PUCAI score, standard blood results and explicit clinical details were recorded on days 0, 3, 
5, 7, 10, 14, at discharge, 1 month, 2 months,  3 months, 6 months, and 12 months after 
randomization. Deterioration after 3 days (i.e. PUCAI increase by at least 20 points) or 
nonresponse after 5 days (i.e. PUCAI decrease by <20 points or absolute PUCAI ≥65) were 
defined as treatment failure. Once PUCAI<35 was achieved, patient discharge was allowed 
and corticosteroids given orally in tapering doses based on a standardized protocol (28). After 
14 days new maintenance therapy with thiopurine/anti-TNF/5-ASA, based on the discretion 
of the treating physician, was allowed. 
 
Randomization, concealment of allocation and blinding 
Patients were randomized by sealed, opaque and numbered envelopes in blocks of four at a 
1:1 ratio. This was not a placebo-controlled study but the investigator scoring the PUCAI at 
each visit and the lab technicians performing the calprotectin and microbiome analyses were 
blinded to the allocation. The clinicians and patients were instructed not to discuss the 
allocation with the investigator. 
Samples  
Stool was collected for fecal calprotectin, C. difficile and microbiome analyses at days 0, 5, 7, 
discharge, 14, and 30, as well as at 2, 3, 6 and 12 months following randomization. Stool 
samples were frozen at -80°C within 4 hours from collection and if that was not possible, 
another sample was collected with 5ml of ethanol as fixative and processed within 30 hours 
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(centrifuged 10min at maximal speed, then supernatant (ethanol) was discarded). Samples 
were shipped on dry ice to Shaare Zedek Medical Center for calprotectin analysis (performed 
by IDK Calprotectin ELISA kit from Immundiagnostik) and to the Broad Institute’s Microbial 
‘Omics Core for microbiome analyses.    
 
DNA extraction and Microbiome (suppl. Methods) 
DNA was extracted from stool using the PowerSoil™ DNA HTP extraction kit (Qiagen). 
Amplicon libraries targeting the V4 region of the 16S rRNA gene were prepared using 
primers 515F and 806rcbc0 and paired-end sequenced on an Illumina MiSeq. Raw sequences 
were quality filtered and merged using PEAR (29), then processed with a custom pipeline 
combining Qiime (30) and Vsearch (31) scripts (Suppl. Methods for more details). Data were 
rariefied to an equal depth of 9,900 seqs per sample to avoid bias. Metagenomic libraries were 
prepared from 100-250pg of DNA using the Nextera XT DNA Library Preparation kit 
(Illumina) and sequenced on a HiSeq 2500 targeting 2.5 Gb of sequence per sample. 
Demultiplexing and generation of fastq files was performed using the Picard suite 
(https://broadinstitute.github.io/picard/command-line-overview.html). Quality control and 
removal of human reads was performed using KneadData 
(http://huttenhower.sph.harvard.edu/kneaddata). MetaPhlAn2 v2.6.0 (32) was used for 
taxonomic profiling and HUMAnN2 v 10.0.0 (33) in Uniref90 mode was used for functional 
analysis. Antibiotic resistance factors were profiled using ShortBRED (34) with markers 
produced from the Comprehensive Antibiotic Resistance Database. All Picard DNA 




Sequence data are available from the Sequence Read Archive 
(https://www.ncbi.nlm.nih.gov/sra) under BioProject PRJNA532645. 
Sample size 
Based on a previous study we anticipated a mean difference in PUCAI of 20 points between 
the treatment groups at day 5 with a SD of 13-20 points (35). We thus needed to study 13 
children and each group to reject the null hypothesis that the population means are equal with 
probability (power) 80% and P<0.05, and with two dropouts, we aimed at 28 children.  
Statistical analyses 
Student's t-test or Wilcoxon rank sum test as appropriate were used to compare continuous 
variables. Categorical data (e.g. remission rates) was compared using Chi square or Fisher’s 
exact, as appropriate. There were 4 children (14%) who were discharged prior to day 5 and 
two that were withdrawn from the trial due to deterioration. Their day 5 parameters were 
imputed using the last observation carried forward (LOCF) principle. 
Shannon index for microbial diversity and Jaccard/Bray-Curtis distances were calculated 
using 'vegan' R package. Spearman correlation was used to associate microbial indexes, 
relative abundances or pairwise distances with PUCAI scores; FDR-correction for multiple 
hypothesis testing was applied as needed. Kruskal-Wallis or paired Wilcoxon were used to 
compare microbial indexes between the two treatment groups. ANOSIM (Analysis of 
Similarities) was used to test for similarities in microbiome composition between the two 
treatment groups. All microbiome analyses were conducted in R and other analysis in SPSS. 





A total of 31 patients were randomized, of whom three were excluded per eligibility criteria 
due to positive infectious screening within 72 hours (one each: Salmonella, Rota virus and 
cytomegalovirus (CMV)), leaving 28 children (mean age 13.9±4.1 years and 23 (82%) 
extensive colitis) in the ITT analysis (Figure 1, Table 1). Eight (29%) were recruited at time 
of first presentation with colitis, the remainder having an acute severe exacerbation of known 
chronic UC.  There were no differences in any of the baseline clinical characteristics between 
the 16 children of the AB+IVCS arm and the 12 of the IVCS arm (Table 1). Of the 16 
children in the AB+IVCS arm, 12 (75%) received the standard cocktail of 
vancomycin/amoxicillin/metronidazole/doxycycline, 2 (12.5%) received ciprofloxacin instead 
of doxycycline because of age (<7 years) and 2 (12.5%) received gentamicin instead of 
doxycycline because of allergy and discretion of the treating physician due to the age of 5 
years.  
 
The mean day-5 PUCAI was lower in the AB+IVCS arm (25±17) than the IVCS arm (40±20; 
p=0.037), meeting the primary endpoint (Figure 2). There were 3 (19%) children in remission 
by day 5 in the AB+IVCS arm compared with 1 (8%) in the IVCS arm (p=0.61). Calprotectin 
was numerally lower in the AB+IVCS vs. the IVCS arm but without statistical significance 
given the large variability of the calprotectin values and the small sample size (Figure 2). The 
need for second line medical therapy at discharge and colectomy rate at 1-year were both low 
and did not differ between the groups (Figure 3), bearing in mind that the sample size had a 
very low power for this outcome. The time from admission to second line medical therapy in 
the five children who required it ranged from 6 to 14 days.   
 
PUCAI scores predicted the need for second line medical therapy in those who received 
infliximab or cyclosporine by discharge both at day 3 (median PUCAI 70 (IQR 60-75) points 
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vs 35 (20-40), respectively; p=0.016) and day 5 (55 (40-60) vs. 30 (10-37.5), p=0.039). Area 
under the ROC curve for the PUCAI to predict need for second line therapy was 0.84 (95%CI 
0.61-1.0) at day 3 and 0.80 (0.56-1.0) at day 5. 
 
Safety 
Eighteen adverse events were recorded in 10 children (63%) from the IVCS+AB group (n=18 
events) and 16 were recorded in 7 children of the IVCS group (58%; p=0.9) within 1 month of 
admission (Suppl. Table 1). Two events in the IVCS+AB group were judged to be possibly 
related to the intervention: dizziness and allergic rash. Both were non-serious but resulted in 
withdrawal of the antibiotics and the children considered as failures in the ITT analysis. 
Besides the one child with mild allergic rash, no other intolerance or allergic reactions to the 
antibiotics were recorded. There were C. difficile infections in both groups throughout the 1-
year follow-up of all patients.  
 
Microbiome 
Stool for microbiome was collected from 25 children pre-treatment. Based on 16S rRNA gene 
sequencing, the microbiome of most patients at admission was highly dysbiotic. These pre-
treatment samples were characterized by low diversity (median Shannon at admission:2.1 , 
range 0.3 to 3.2; as compared to samples taken during remission: 2.7, range 1.3 to 3.5; 
p=0.002) and high relative abundance of Gammaproteobacteria (median relative abundance: 
20%, range 0.04% to 97%; compared to remission samples: median 0.02%, range 0.02% to 
57%; p=0.0003; see also Figure 4 for family-level and Supplemental Figure 1 for genus-
level). In the IVCS arm, microbial diversity at admission strongly correlated with day 5 
PUCAI (r=0.72, p=0.01; Figure 5). In contrast, in the IVCS+AB arm, no such association was 




Highly dominant genera, comprising over 33% of the microbiome, were observed in 17 
(68%) of the patients before treatment (Table 2). Escherichia, Haemophilus and Enterobacter, 
all of which belong to the class Gammaproteobacteria, which rarely dominates the healthy gut 
microbiome, were abundant in 9 patients (36%), and comprised 40-90% of their microbiome.  
To determine which species were contributing to this Proteobacteria signal, we generated 
metagenomic data which allows species-level resolution for taxonomic profiling. Prior to 
treatment at “day 0”, we observed high relative abundance of Escherichia coli, Klebsiella 
pneumoniae, and Haemophilus parainfluenzae (Figure 6A).  
 
To identify microbial differences associated with remission, we next compared the microbial 
profiles of the initial samples to the samples from a patient’s first remission time point with a 
particular focus on Proteobacteria. At first remission, none of the IVCS patients showed 
Proteobacteria blooms, whereas several patients who received IVCS+AB continued to display 
Proteobacteria dominance which were also more common in this group at baseline (Figure 
6B).  
 
Antibiotic treatment, as expected, exerted a large effect on the microbial population. The 
microbiome of samples taken during treatment clustered according to treatment type 
(ANOSIM p=0.001, r=0.67, Suppl. Figure 2A) and displayed an expansion of taxa belonging 
to the Gammaproteobacteria (mainly Escherichia and Haemophilus) coupled to a reduction of 
multiple taxa belonging to the Clostridiales and Bacterodiales orders (to which most known 
butyrate producers belong). Accordingly, microbial diversity was strongly reduced during 
antibiotic treatment. Nevertheless, rapid recovery of the microbiome was observed as early as 
2 months after cessation of antibiotic treatment (Suppl. Figure 3). While some patients from 
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IVCS+AB group tended to higher Escherichia levels following treatment, overall post-
treatment remission samples did not segregate according to type of treatment received (Suppl. 
Figure 2B, ANOSIM p=0.2, r=0.03). 
 
A potential concern in the context of antibiotic treatment is the development of antibiotic 
resistance. We therefore quantified within-patient shifts in the abundance of antimicrobial 
resistance factors over time (Suppl. Figure 4). Overall, increased resistance against 
ciprofloxacin, doxycycline and tetracycline was observed by day 30 in patients receiving 
antibiotics but not in those who received steroids-only. We did not witness a significant 
increase for amoxicillin or metronidazole. These resistance levels returned to baseline levels 
after 90 days, with the exception of doxycycline resistance, which remained elevated for up to 




In this first RCT ever conducted in pediatric ASC, we found that an antibiotic cocktail of four 
oral antibiotics in addition to standard IVCS, was effective in reducing the PUCAI score after 
5 treatment days as compared with IVCS alone. Secondary endpoints of remission rate and 
calprotectin value were numerically better in the intervention arm but did not reach statistical 
significance in this small study. The need for second-line medical therapy or colectomy was 
similar between the treatment arms. This pilot study was not powered and did not aim to show 
a difference in these endpoints. The number of children requiring second line therapy was 
lower than previously reported in both groups (18% compared with previous reports of 30-
35% (36)). Considering the observed ~20% steroid-failure rate and even if the treatment 
benefit of antibiotics is as high as 30% in avoiding second line treatment (i.e. 14% in the 
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intervention arm), randomization of 1228 children would be required to show such a 
difference with a power of 80%. Nonetheless, the effect of antibiotics has previously been 
inversely correlated with disease activity in pediatric UC (20) and thus the observed added 
benefit of the cocktail in our trial of severe colitis, may be encouraging.  
 
Using both 16S rRNA gene sequencing data (which allows detection of rare taxa) and 
metagenomic data (which allows species-level classification), we have examined for the first 
time pre-treatment microbiome of patients admitted for ASC. Interestingly, two-thirds of 
children had a dominant bacterial genus at admission, possibly reflecting the reduction in 
microbial diversity associated with active inflammation. Diarrhea and oxidative stress favor 
taxa which are fast growing and facultatively aerobic, as are most gut proteobacterial species; 
adhesion and penetration of the gut epithelial barrier have been documented for some strains 
of the genus Escherichia, which was especially dominant at admission (37).  
 
It is tempting to assume that some of the severe steroid-resistant ASC attacks may be 
secondary to an unknown uncultured infection underlying the severe mucosal inflammation. 
Indeed, this has been described with CMV (38), cryptosporidium (39) and C. difficile (40), 
that are more commonly seen in patients with acute UC than in the general population. 
However, in the IVCS+AB group we found no correlation between microbial features at 
admission and clinical response five days later. An alternative hypothesis is that the broad-
spectrum coverage of the Jerusalem cocktail led to an overall decrease in bacterial abundance, 




In contrast to what we observed with the antibiotics-treated group, microbial diversity at 
admission was negatively correlated with response in the steroid-only treated group. Since a 
diverse gut microbiome is considered beneficial, this finding may appear paradoxical. 
However, microbial diversity has been shown to correlate with bacterial loads (41, 42). Thus, 
patients with high microbial diversity at admission may have larger antigenic exposure and 
consequently a lower response. This explanation is consistent with the lack of correlation 
between diversity and response observed in the IVCS+AB treated group, as antibiotics reduce 
the bacterial load across all the patients. 
 
PUCAI scores predicted the need for second line medical therapy at days 3 and 5 with high 
accuracy. This reinforces previous findings (35) and ECCO-ESPGHAN guidelines (23) in 
which second line medical therapy is based on the PUCAI score at these time-points.   
 
There are now ample of data to implicate the microbiome as a main factor in the occurrence 
of IBD (43). Data to support the role of antibiotics in treating a subset of resistant UC are 
steadily accumulating, both from RCT’s in adults (6, 7) (8, 11) (12, 13) (14) (15) and case 
series in children (18-20). The diversity of studied regimens and treatment protocols, 
however, hampers our ability to draw conclusions from the research arena to clinical practice. 
We thus based our cocktail on previously reported successful experience with the Japanese 
cocktail and vancomycin, while allowing other antibiotics for allergic and younger children in 
whom doxycycline is contraindicated. Concerns regarding adverse events reduce the 
feasibility of using antibiotics for long periods and we show that the resistance was transient 
for all agents except doxycycline. Moreover, ASC is an acute, often dramatic, scenario with 
significant morbidity, and a potential benefit might outweigh the risk of drug resistance. 
Nonetheless, this was a pilot RCT and antibiotics cannot be routinely recommended until 
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larger studies demonstrate a reduced need for second line treatment or colectomy. 
Furthermore, our findings on the microbiome during episodes of ASC may facilitate future 
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LEGENDS to FIGURES 
Figure 1: CONSORT study flowchart 
Footnote: ITT, intention to treat. 
Figure 2: Pediatric UC activity index (PUCAI) and fecal calprotectin values stratified by the 
treatment groups 
Figure 3: Second line medical and surgical management by discharge (DC) and 1 year (yr). 
Footnote: IFX, infliximab; CysA, cyclosporine A. 
Figure 4: Microbial dysbiosis at family-level on admission from 16S rRNA gene data  
Footnote: Each bar represents the pre-treatment microbiome of a single patient rank-ordered 
of increasing Gammaproteobacteria relative abundance. Rare families (i.e. <3% across all 
samples) were excluded. The major gut phyla are color coded: shades of brown for 
Bacteroidetes; purple, green and blue for Lactobacillales, Clostridiales, and Erysipelotrichales 
orders of the Firmicutes phylum; Proteobacterial families are in shades of red.  
Figure 5: Correlation between microbial diversity at admission and PUCAI score on day 5. 
Figure 6: Proteobacterial species abundance from metagenomic data per participant prior to 
treatment (day 0) and on the day of first remission. Proteobacteria at < 5% abundance were 




Suppl. Figure 1: Microbiome at genus-level on admission from 16S rRNA gene data. Each 
bar represents the pre-treatment microbiome of a single patient rank-ordered of increasing 
relative abundance of Gammaproteobacteria 
Footnote: Rare genrea (i.e. <3% across all samples) were excluded. The major gut phyla are 
color coded: shades of brown for Bacteroidetes; purple, green and blue for Lactobacillales, 
Clostridiales, and Erysipelotrichales orders of the Firmicutes phylum; Proteobacterial families 
are in shades of red.  
Suppl. Figure 2: Clustering of samples according to 16S rRNA gene microbial composition 
during and after treatment (A) samples taken during treatment; (B) samples taken during 
remission (i.e. PUCAI<10) and at least 2 months after treatment. 
Footnote: Principle Coordinate Analysis used for dimension reduction and visualization of 
Bray-Curtis distance matrix. Similar results obtained if using Jaccard distance matrix (during-
treatment ANOSIM p-value=0.001, r=0.44; post-treatment ANOSIM p-value=0.4, r=0).  
Suppl. Figure 3: Microbial features across time in both treatment groups based on 16S rRNA 
gene sequencing data. A: Shannon diversity index; B: Clostridiales order (relative 
abundance); C: Gammaproteobacteria class; D: Escherichia (relative abundance).  
Footnote: Time-points: T0: admission, T1: during treatment; T2-T4: post-treatment (T2: >21 
& <60 days; T3:>60 & <180 days,T4: >180 days & <1 year).   
Suppl. Figure 4: Fold change in antimicrobial resistance factors relative to baseline.  
Footnote: The sum of resistance factors was calculated for each of the four antibiotics for 
each sample, respectively. Within each participant, log fold change between day 0 antibiotic 
resistance and antibiotic resistance in the follow-up sample was then calculated. A fold 
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change of 0 indicates that resistance to a given antimicrobial did not change within a 





Table 1: Baseline characteristics of enrolled children at admission. Counts (%), medians 
(interquartile range) or means ± SD are presented as appropriate for the data distribution. 
None of the variables were significantly different between the groups. 






Males 15 (47%) 10 (63%) 5 (42%) 
Age (years) 13.9±4.1 13.5 ± 4.7 14.6 ± 3.3 
Range (years) 4.4-18 4.4-18 8.6-18 
Disease duration (months) 7 (0-20) 11 (0.5-20) 2. 5 (0-23) 
First attack 8 (29%) 4 (25%) 4 (33%) 
Exacerbation 20 (71%) 12 (75%) 8 (67%) 
Disease extent    
Left sided (E2) 5 (18%) 4 (25%) 1 (8%) 
Extensive/pancolitis (E3+E4) 23 (82%) 12 (75%) 11 (92%) 
PGA of disease activity (mm) 75 ± 9 77 ± 10 73 ± 6 
PUCAI at admission 74 ± 7 71 ± 12 75 ± 7  
# severe (i.e. ≥65points) 28 (100%) 16 (100%) 12 (100%) 
Fecal calprotectin  1780 (1188-2890) 1733 (1125-2890) 1840 (1433-2825) 
C-reactive protein (mg/dL) 1.0 (0.6-2.8) 0.73 (0.4-2.0) 1.2 (0.7-3.2) 
ESR (mm) 27 (17-46) 33 (16-50) 22 (18-33) 
Albumin (mg/L) 3.8 (3.4-4.1) 3.7 (3.3-4.1) 4 (3.7-4.1) 
Hemoglobin (mg/L) 11.9 (10.3-12.8) 11.3 (9-11.8) 12.3 (11.2-12.8) 
Treatment at admission     
Oral prednisone 7 (25%) 3 (19%) 4 (33%) 
Thiopurine 6 (21%) 3 (19%) 3 (25%) 
Anti-TNF 4 (14%) 3 (19%) 1 (8%) 
 
PUCAI, Pediatric Ulcerative Colitis Activity Index; PGA, physicians’ global assessment; 














Bacteroides 6 0.34-0.61 Bacteroidetes 
Parabacteroides 1 0.43 Bacteroidetes 
Faecalibacterium 1 0.57 Firmicutes  




Shigella 6 0.4-0.97 
Proteobacteria (class: 
Gammaproteobacteria) 











(n=5 AE in 4 
children) 
IVCS  
(n=6 AE in 5 
children) 
Non-serious adverse events (AE)a 4 (25%) 2 (16.7%) 
Nausea 1 (6.3%) 0 (0%) 
Dizziness/headache 1 (6.3%) 1 (8.3%) 
Arthralgia 0 (0%) 1 (8.3%) 
Treatment reactions  2 (12.5%)b 0 
Serious adverse events (SAE)a 1 (6.3%) 4 (33.3%) 
Disease exacerbation 1 (6.3%) 2 (16.7%) 
Vomiting 0 (0%) 1 (8.3%) 
Infections 0 (0 1 (8.3%) 
a None of the SAE were judged as drug-related; 3 AEs were likely/possibly related to the 
treatment 






DNA extraction, 16S rRNA amplicon and metagenomic data generation 
DNA was extracted from thawed stool samples using the DNeasy PowerSoil HTP 96 kit (Qiagen 
product number 12955-4). 16S rRNA gene libraries targeting the V4 region of the 16S rRNA gene 
were prepared by first normalizing template concentrations and determining optimal cycle number by 
way of qPCR.  Using primers 515F and 806rcbc0. To ensure minimal over-amplification, each sample 
was diluted to the lowest concentration sample, amplifying with this sample optimal cycle number for 
the library construction PCR using the Golay primer set (Caporaso, 2011 and 2012).  Four replicates 
were pooled, cleaned and normalized prior to sequencing on an Illumina MiSeq in paired-end mode 
(2x175bp) using custom index 5’-ATTAGAWACCCBDGTAGTCC GG CTGACTGACT-3’ and 
custom Read 1 (5’-TATGGTAATT GT GTGYCAGCMGCCGCGGTAA-3’) and Read 2 (5’-








For metagenomic library construction, DNA samples were quantified by Quant-iT PicoGreen dsDNA 
Assay (Life Technologies) and normalized to a concentration of 50pg/uL.  Libraries were prepared 
from 100-250pg of DNA using the Nextera XT DNA Library Preparation kit (Illumina) according to 
the manufacturer’s protocol, with reaction volumes scaled accordingly. Insert sizes and concentrations 
for each library pool of 96 samples were determined using an Agilent Bioanalyzer DNA 1000 kit 
(Agilent Technologies). Libraries were sequenced at the Broad Institute Genomics Platform on a 
HiSeq 2500 targeting 2.5 Gb of sequence per sample with 101 bp paired-end reads. Post-sequencing 
de-multiplexing and generation of BAM and Fastq files are generated using the Picard suite 
 (https://broadinstitute.github.io/picard/command-line-overview.html). 
 
Taxonomic and functional profiling of metagenomic data 
The KneadData pipeline was used to quality control raw sequencing reads. Briefly, the pipeline first 
quality trims the 3’ ends of reads using Trimmomatic and then filters out all reads <60 nt in length. 
Reads mapping to human reference genome hg19 using bowtie2 are then removed. Taxonomic 
profiling of collected stool samples was performed using MetaPhlAn2 v2.6.0. MetaPhlAn2 maps reads 
to marker genes unique to a given microbial clade in order to estimate the abundance of that clade. In 
this analysis, we considered the resulting abundance profiles at species level. 
Functional profiling for metagenomic features was performed using HUMAnN2 v 10.0.0 in Uniref90 
mode. HUMAnN2 first maps metagenomic reads to the pangenomes of species identified by 
MetaPhlAn2. Coding sequences in pangenomes are assigned to UniRef90 families. Reads failing to 
map to a pangenome are then mapped to UniRef90 via translated search using DIAMOND. Hits are 
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scored by alignment quality, sequence length, and sequence coverage. Gene-level outputs are given in 
reads per kilobase units and stratified by species contribution. Gene abundances can be mapped to 
other functional annotation systems based on UniProt annotations. In this study, genes were remapped 
to their corresponding Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthologies. KEGG 
Orthologs were then grouped into their corresponding modules by total sums. 
Samples were excluded from analysis if fewer than 5,000,000 reads were present in the sample after 
QC filtering and removal of human reads. Metagenomically determined species were considered 
absent from a sample if their abundance was less than 0.25% of the sample or if the species was 
present in fewer than two samples across the cohort. 
 
Antibiotic resistance factor profiling 
Antibiotic resistance factors were profiled using ShortBRED with markers produced from the 
Comprehensive Antibiotic Resistance Database. Briefly ShortBRED produces family-level markers by 
finding highly conserved sequence regions within orthologous gene families and then quantifies reads 
aligning to these makers, normalizing by the length of the marker. 
Pseudocounts of one half of the minimum non-zero observed value of a feature were added to each 
observation of zero feature abundance per antimicrobial resistance feature as quantified by 
shortBRED. 
shortBRED marker family determination: resistance factors for 6 antibiotics were determined by 
parsing through all CARD ontologies with a particular focus on the relational keywords 
“confers_resistance_to:” and references to any of these antibiotics. 
 
Doxycycline 
'ARO:3000186', 'ARO:3000190', 'ARO:3000191', 'ARO:3000192', 'ARO:3000193', 'ARO:3000194', 




'ARO:3000386', 'ARO:3000391', 'ARO:3000419', 'ARO:3000421', 'ARO:3000448', 'ARO:3000753', 
'ARO:3000769', 'ARO:3000822', 'ARO:3001327', 'ARO:3002547', 'ARO:3002790', 'ARO:3003032', 
'ARO:3003038', 'ARO:3003294', 'ARO:3003295', 'ARO:3003296', 'ARO:3003297', 'ARO:3003298', 
'ARO:3003304', 'ARO:3003305', 'ARO:3003306', 'ARO:3003307', 'ARO:3003308', 'ARO:3003309', 
'ARO:3003310', 'ARO:3003311', 'ARO:3003312', 'ARO:3003315', 'ARO:3003316', 'ARO:3003317', 
'ARO:3003684', 'ARO:3003789', 'ARO:3003817', 'ARO:3003818', 'ARO:3003844', 'ARO:3003921', 
'ARO:3003926', 'ARO:3003939', 'ARO:3003947', 'ARO:3003964', 'ARO:3004048', 'ARO:3004051', 
'ARO:3004052', 'ARO:3004053', 'ARO:3004066', 'ARO:3004068', 'ARO:3004078', 'ARO:3004079', 




'ARO:3000873', 'ARO:3000900', 'ARO:3001396', 'ARO:3001397', 'ARO:3003041', 'ARO:3003042', 




'ARO:3000026', 'ARO:3000165', 'ARO:3000166', 'ARO:3000167', 'ARO:3000168', 'ARO:3000173', 
'ARO:3000174', 'ARO:3000175', 'ARO:3000177', 'ARO:3000178', 'ARO:3000179', 'ARO:3000180', 
'ARO:3000181', 'ARO:3000182', 'ARO:3000183', 'ARO:3000186', 'ARO:3000190', 'ARO:3000191', 
'ARO:3000192', 'ARO:3000193', 'ARO:3000194', 'ARO:3000195', 'ARO:3000196', 'ARO:3000197', 
'ARO:3000205', 'ARO:3000343', 'ARO:3000373', 'ARO:3000384', 'ARO:3000386', 'ARO:3000464', 
'ARO:3000476', 'ARO:3000478', 'ARO:3000481', 'ARO:3000556', 'ARO:3000561', 'ARO:3000565', 
'ARO:3000566', 'ARO:3000567', 'ARO:3000569', 'ARO:3000572', 'ARO:3000573', 'ARO:3000770', 
'ARO:3000771', 'ARO:3000772', 'ARO:3000797', 'ARO:3000799', 'ARO:3001328', 'ARO:3002870', 
'ARO:3002871', 'ARO:3002892', 'ARO:3002893', 'ARO:3002894', 'ARO:3003029', 'ARO:3003032', 
'ARO:3003038', 'ARO:3003054', 'ARO:3003062', 'ARO:3003196', 'ARO:3003410', 'ARO:3003411', 
'ARO:3003499', 'ARO:3003510', 'ARO:3003694', 'ARO:3003697', 'ARO:3003964', 'ARO:3003980', 
'ARO:3003981', 'ARO:3004031', 'ARO:3004034', 'ARO:3004051', 'ARO:3004052', 'ARO:3004053', 
'ARO:3004062', 'ARO:3004076', 'ARO:3004078', 'ARO:3004079', 'ARO:3004080', 'ARO:3004128', 
'ARO:3004441', 'ARO:3004442', 'ARO:3004470' 
 
 
